Review



tars  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Santa Cruz Biotechnology tars
    <t>TARS</t> mRNA levels are increased in ovarian cancer and reduced by neo - adjuvant chemotherapy. Data were obtained from GEO dataset GDS 2785. The study analyzed mRNA by GeneChip microarray in ovarian tissue from 10 patients with benign conditions, 9 patients with untreated adenocarcinoma, and 24 patients with adenocarcinoma treated with carboplatin/taxol prior to surgery (+Chemo) . Shown are expression profile comparisons for A , TARS, B , VEGF, C , SARS and D , YARS. Differences between groups was significant for TARS and VEGF as determined by ANOVA Kruskal Wallis analysis, *p < 0.0001 compared with benign, #p < 0.001 compared with carcinoma.
    Tars, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/immunohistochemistry+microarray+based+expression+data/ThrRS+Antibody/pmc04155084-65-21-24
    Average 90 stars, based on 2 article reviews
    tars - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer"

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer

    Journal: BMC Cancer

    doi: 10.1186/1471-2407-14-620

    TARS mRNA levels are increased in ovarian cancer and reduced by neo - adjuvant chemotherapy. Data were obtained from GEO dataset GDS 2785. The study analyzed mRNA by GeneChip microarray in ovarian tissue from 10 patients with benign conditions, 9 patients with untreated adenocarcinoma, and 24 patients with adenocarcinoma treated with carboplatin/taxol prior to surgery (+Chemo) . Shown are expression profile comparisons for A , TARS, B , VEGF, C , SARS and D , YARS. Differences between groups was significant for TARS and VEGF as determined by ANOVA Kruskal Wallis analysis, *p < 0.0001 compared with benign, #p < 0.001 compared with carcinoma.
    Figure Legend Snippet: TARS mRNA levels are increased in ovarian cancer and reduced by neo - adjuvant chemotherapy. Data were obtained from GEO dataset GDS 2785. The study analyzed mRNA by GeneChip microarray in ovarian tissue from 10 patients with benign conditions, 9 patients with untreated adenocarcinoma, and 24 patients with adenocarcinoma treated with carboplatin/taxol prior to surgery (+Chemo) . Shown are expression profile comparisons for A , TARS, B , VEGF, C , SARS and D , YARS. Differences between groups was significant for TARS and VEGF as determined by ANOVA Kruskal Wallis analysis, *p < 0.0001 compared with benign, #p < 0.001 compared with carcinoma.

    Techniques Used: Adjuvant, Microarray, Expressing

    TARS expression increases with stage of ovarian cancer. A . Tissues were stained for TARS by immunohistochemistry and counter-stained with Mayers’ hematoxylin. Images were scored blindly by 2 independent investigators and tumor identification was later confirmed by a pathologist (SLM). Shown are 10x images from (1) normal ovary and examples of TARS score increasing with extent of disease (2–4), Bar = 100 μm. B . Graph representing average scores where high stage is ≥ stage 3; statistical significance determined by one-way ANOVA. For more detailed statistics, see Table for Pearson’s Correlations. C . Shown is a graph of individual patient TARS tumor scores grouped according to FIGO stage of disease (i.e. Stage 3.75 = FIGO 3C).
    Figure Legend Snippet: TARS expression increases with stage of ovarian cancer. A . Tissues were stained for TARS by immunohistochemistry and counter-stained with Mayers’ hematoxylin. Images were scored blindly by 2 independent investigators and tumor identification was later confirmed by a pathologist (SLM). Shown are 10x images from (1) normal ovary and examples of TARS score increasing with extent of disease (2–4), Bar = 100 μm. B . Graph representing average scores where high stage is ≥ stage 3; statistical significance determined by one-way ANOVA. For more detailed statistics, see Table for Pearson’s Correlations. C . Shown is a graph of individual patient TARS tumor scores grouped according to FIGO stage of disease (i.e. Stage 3.75 = FIGO 3C).

    Techniques Used: Expressing, Staining, Immunohistochemistry

    Pearson Correlation Matrix for  TARS  expression in ovarian cancer patient samples
    Figure Legend Snippet: Pearson Correlation Matrix for TARS expression in ovarian cancer patient samples

    Techniques Used: Expressing

    TARS is secreted by SK - OV - 3 ovarian cancer cells. (A) SK-OV-3 cells were treated with TNF-α (50 ng/ml) or exposed to 2% O 2 for 24 h where indicated. Media was concentrated 20-fold to accommodate 25% onto the gel and compared to 5% of the cell lysate. Shown is a representative Western blot probed for TARS and β-tubulin, n = 4. (B) Cells were treated as in (A) . After 24 h the level of TARS in the supernatant was determined by ELISA, *p < 0.05, n = 3. Cell membrane integrity was confirmed using the lactate dehydrogenase assay CytoTox-ONE™ and by lack of β-tubulin in media samples. (C) Relative mRNA levels for TARS, VEGF and IL-1β were determined by RT-qPCR following treatment as in (A) ; *p < 0.001, **p < 0.0001, n = 4.
    Figure Legend Snippet: TARS is secreted by SK - OV - 3 ovarian cancer cells. (A) SK-OV-3 cells were treated with TNF-α (50 ng/ml) or exposed to 2% O 2 for 24 h where indicated. Media was concentrated 20-fold to accommodate 25% onto the gel and compared to 5% of the cell lysate. Shown is a representative Western blot probed for TARS and β-tubulin, n = 4. (B) Cells were treated as in (A) . After 24 h the level of TARS in the supernatant was determined by ELISA, *p < 0.05, n = 3. Cell membrane integrity was confirmed using the lactate dehydrogenase assay CytoTox-ONE™ and by lack of β-tubulin in media samples. (C) Relative mRNA levels for TARS, VEGF and IL-1β were determined by RT-qPCR following treatment as in (A) ; *p < 0.001, **p < 0.0001, n = 4.

    Techniques Used: Western Blot, Enzyme-linked Immunosorbent Assay, Membrane, Lactate Dehydrogenase Assay, Quantitative RT-PCR

    Correlation of TARS levels detected in serum with TARS expression in ovarian cancer. Graphs represent scatter dot plots (mean ± SD) of patient data for TARS serum levels against (A) Stage of cancer and (B) TARS tumor tissue score. The correlation (r-value) and p-values were calculated by a Pearson correlation matrix (see Table ).
    Figure Legend Snippet: Correlation of TARS levels detected in serum with TARS expression in ovarian cancer. Graphs represent scatter dot plots (mean ± SD) of patient data for TARS serum levels against (A) Stage of cancer and (B) TARS tumor tissue score. The correlation (r-value) and p-values were calculated by a Pearson correlation matrix (see Table ).

    Techniques Used: Expressing

    Hazard ratios for the association of  TARS  with mortality using univariate Cox proportional hazard models
    Figure Legend Snippet: Hazard ratios for the association of TARS with mortality using univariate Cox proportional hazard models

    Techniques Used:

    Multivariate Cox proportional hazard model for  TARS  tumor score
    Figure Legend Snippet: Multivariate Cox proportional hazard model for TARS tumor score

    Techniques Used:

    Related Articles

    other:

    Article Title: Inhibition of MUC1 biosynthesis via threonyl-tRNA synthetase suppresses pancreatic cancer cell migration
    Article Snippet: Anti-MUC1 (cat# ab109185) was purchased from Abcam (Cambridge, UK), anti-MUC1 (cat# sc-7313), anti-ThrRS (cat# sc-166146), anti-c-Myc (cat# sc-40), and anti-AlaRS (cat# sc-98547) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), anti-alpha-tubulin (cat# T6074) was purchased from Sigma-Aldrich (St Louis, MO, USA), and anti-puromycin (cat# MABE343) was purchased from Millipore (Billerica, MA, USA).

    Article Title: Inhibition of MUC1 biosynthesis via threonyl-tRNA synthetase suppresses pancreatic cancer cell migration.
    Article Snippet: Anti-MUC1 (cat# ab109185) was purchased from Abcam (Cambridge, UK), anti-MUC1 (cat# sc-7313), anti-ThrRS (cat# sc-166146), anti-cMyc (cat# sc-40), and anti-AlaRS (cat# sc-98547) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), anti-alpha-tubulin (cat# T6074) was purchased from Sigma-Aldrich (St Louis, MO, USA), and anti-puromycin (cat# MABE343) was purchased from Millipore (Billerica, MA, USA).

    SDS Page:

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [13]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [ ]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Western Blot:

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [13]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [ ]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Control:

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [13]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [ ]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Lysis:

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [13]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..

    Article Title: Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer
    Article Snippet: .. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in [ ]. β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis. ..



    Similar Products

    86
    Human Protein Atlas immunohistochemistry microarray based expression data
    Immunohistochemistry Microarray Based Expression Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/immunohistochemistry+microarray+based+expression+data/data+immunohistochemistry/bio_rxiv__64898__2025__12__09__693329-120-11-17
    Average 86 stars, based on 1 article reviews
    immunohistochemistry microarray based expression data - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results